~ Buy the LOCAMETZ (gallium ga-68 gozetotide) Drug Profile, 2024 PDF Report in the Report Store ~

LOCAMETZ Drug Patent Profile

Which patents cover Locametz, and what generic alternatives are available?

Locametz is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-four patent family members in fifteen countries.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.

DrugPatentWatch^® Generic Entry Outlook for Locametz

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 15, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for LOCAMETZ

International Patents:	34
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for LOCAMETZ
What excipients (inactive ingredients) are in LOCAMETZ?	LOCAMETZ excipients list
DailyMed Link:	LOCAMETZ at DailyMed

See drug prices for LOCAMETZ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LOCAMETZ

NDA:

215841

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for LOCAMETZ

LOCAMETZ is protected by one US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting LOCAMETZ

FDA Regulatory Exclusivity protecting LOCAMETZ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LOCAMETZ	gallium ga-68 gozetotide	POWDER;INTRAVENOUS	215841-001	Mar 23, 2022		RX	Yes	Yes			Y	Y
Novartis	LOCAMETZ	gallium ga-68 gozetotide	POWDER;INTRAVENOUS	215841-001	Mar 23, 2022		RX	Yes	Yes

International Patents for LOCAMETZ

When does loss-of-exclusivity occur for LOCAMETZ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

New Zealand

Poland

Portugal

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LOCAMETZ around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2018150350	ＰＳＭＡ結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
Japan	6596479
Poland	2187965
European Patent Office	3388086	CONJUGUÉS COMPRENANT UN LIGAND DU PSMA ET UN LIEUR ET PROCÉDÉS POUR LEUR UTILISATION (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)
European Patent Office	3858347	CONJUGUÉS LIGAND-LIEUR DE LIAISON AU PSMA ET PROCÉDÉS POUR UTILISER CEUX-CI (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING)